Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.23.1
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Research and development expenses $ 1,267,453 $ 1,169,254  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,127,361 1,787,152  
Depreciation and amortization [2] 27,555 22,878  
Loss from operations [3] (2,422,369) (2,979,284)  
Other expense [4] 946,039 (7,961)  
Net loss (1,476,330) (2,987,245)  
United States 2,367,586   $ 4,371,606
Capital expenditures 15,068 42,017  
UNITED STATES      
United States 1,776,386 3,185,236  
Non-US [Member]      
United States 591,200 416,889  
Diagnostics Segment [Member]      
Research and development expenses 1,170,553 989,887  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 0 0  
Depreciation and amortization [2] 9,275 6,040  
Loss from operations [3] (1,179,828) (995,927)  
Other expense [4] 0 0  
Net loss (1,179,828) (995,927)  
Capital expenditures 15,068 40,221  
Diagnostics Segment [Member] | UNITED STATES      
United States 0 150,920  
Diagnostics Segment [Member] | Non-US [Member]      
United States 578,272 393,753  
Therapeutics Segment [Member]      
Research and development expenses 96,900 179,367  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 2,178    
Depreciation and amortization [2] 0 0  
Loss from operations [3] (99,078) (179,367)  
Other expense [4] 0 0  
Net loss (90,078) (179,367)  
Capital expenditures 0 0  
Therapeutics Segment [Member] | UNITED STATES      
United States 0 0  
Therapeutics Segment [Member] | Non-US [Member]      
United States 0 0  
Therapeutics Segment [Member] | License [Member]      
Selling, general and administrative expenses, excluding depreciation and amortization [1]   0  
Corporate Segment [Member]      
Research and development expenses 0    
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,125,183 1,787,152  
Depreciation and amortization [2] 18,280 16,838  
Loss from operations [3] (1,143,463) (1,803,990)  
Other expense [4] 946,039 (7,961)  
Net loss (197,424) (1,811,951)  
Capital expenditures 0 1,796  
Corporate Segment [Member] | UNITED STATES      
United States 1,776,386 3,034,316  
Corporate Segment [Member] | Non-US [Member]      
United States $ 12,928 23,136  
Corporate Segment [Member] | Royalty [Member]      
Research and development expenses   $ 0  
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2] Depreciation and amortization are reflected in selling, general and administrative expenses ($27,555 and $22,878 for the three-month periods ended March 31, 2023 and 2022, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4] Amounts consist primarily of gain on amendment of contracts, interest income and interest expense, which are not currently allocated to our individual reportable segments.